NCT03284502: Cobimetinib and HM95573 in Patients With Locally Advanced or Metastatic Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: RAS, RAF
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 19 Years and older (Adult), Senior)
Location of Metastases: 
Additional Notes: Must have RAS- or RAF-mutation
Exclusions: Known brain metastases that are untreated, symptomatic, or require therapy to control symptoms

Comments are closed.

Up ↑